Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksODX.L Regulatory News (ODX)

  • There is currently no data for ODX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

11 May 2022 15:28

RNS Number : 1566L
Omega Diagnostics Group PLC
11 May 2022
 

TR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN

gb00b1vcp282

Issuer Name

OMEGA DIAGNOSTICS GROUP PLC

UK or Non-UK Issuer

UK

2. Reason for Notification

An acquisition or disposal of voting rights; An acquisition or disposal of financial instruments

3. Details of person subject to the notification obligation

Name

Spreadex LTD

City of registered office (if applicable)

St. Albans

Country of registered office (if applicable)

United Kingdom

4. Details of the shareholder

Full name of shareholder(s) if different from the person(s) subject to the notification obligation, above

 

City of registered office (if applicable)

 

Country of registered office (if applicable)

 

5. Date on which the threshold was crossed or reached

10-May-2022

6. Date on which Issuer notified

11-May-2022

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8.A)

% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer

Resulting situation on the date on which threshold was crossed or reached

5.570233

4.327216

9.897449

23029621

Position of previous notification (if applicable)

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)

Number of direct voting rights (DTR5.1)

Number of indirect voting rights (DTR5.2.1)

% of direct voting rights (DTR5.1)

% of indirect voting rights (DTR5.2.1)

GB00B1VCP282

12960951

5.570233

Sub Total 8.A

12960951

5.570233%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument

Expiration date

Exercise/conversion period

Number of voting rights that may be acquired if the instrument is exercised/converted

% of voting rights

CFD/ Spread bet

10068670

4.327216

Sub Total 8.B1

10068670

4.327216%

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument

Expiration date

Exercise/conversion period

Physical or cash settlement

Number of voting rights

% of voting rights

 

Sub Total 8.B2

9. Information in relation to the person subject to the notification obligation

1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.

Ultimate controlling person

Name of controlled undertaking

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

 

10. In case of proxy voting

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

11. Additional Information

Samuel Bottomley01727 895011

12. Date of Completion

11-May-2022

13. Place Of Completion

UK

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLUAUSRUNUVAAR
Date   Source Headline
22nd Oct 20197:00 amRNSTrading Update and Notice of Interim Results
15th Oct 20192:29 pmRNSHolding(s) in Company
14th Oct 20198:18 amRNSHolding(s) in Company
14th Oct 20197:00 amRNSHolding(s) in Company
11th Oct 20198:00 amRNSHolding(s) in Company
10th Oct 201910:30 amRNSResult of General Meeting
27th Sep 201910:00 amRNSNotice of AGM and posting of annual report
23rd Sep 20197:01 amRNSPlacing & Subscription, Notice of General Meeting
23rd Sep 20197:00 amRNSFinal Results
16th Sep 20197:00 amRNSUpdate on VISITECT® CD4 Advanced Disease
10th Sep 20197:00 amRNSPurchase Order for Chinese Food Detective® test
20th Aug 20197:00 amRNSFirst VISITECT® CD4 Advanced Disease Test Order
16th Aug 201911:00 amRNSRe. Results, Trading Update & Nigerian CD4 Order
8th Aug 20197:00 amRNSInvestor Briefing
6th Jun 20197:00 amRNSAnnouncement of Results
5th Jun 20191:37 pmRNSHolding(s) in Company
3rd Jun 20191:43 pmRNSHolding(s) in Company
22nd May 20197:00 amRNSSubscription to raise c.£635,000
17th Apr 20197:00 amRNSTrading Update
18th Mar 20197:00 amRNSCE-Mark for VISITECT® CD4 Advanced Disease test
6th Mar 20197:00 amRNSVISITECT® CD4 update
1st Mar 20197:00 amRNSBoard Appointment
29th Jan 20197:00 amRNSVISITECT® CD4 Advanced Disease test update
10th Dec 20189:00 amRNSDirectorate Change
3rd Dec 20187:00 amRNSInterim results
19th Oct 20184:27 pmRNSHolding(s) in Company
10th Oct 20187:00 amRNSTrading Update and Notice of Interim Results
8th Oct 20182:38 pmRNSHolding(s) in Company
27th Sep 20187:00 amRNSAllergy CE-Mark and first Purchase Order
14th Sep 201811:25 amRNSResult of AGM
10th Sep 20188:56 amRNSHolding(s) in Company
6th Aug 20187:01 amRNSFinal Results
6th Aug 20187:00 amRNSVISITECT® CD4 Advanced Disease Development Update
30th Jul 20185:29 pmRNSHolding(s) in Company
18th Jul 20187:00 amRNSVISITECT® CD4 commercialisation update
12th Jul 20187:00 amRNSInvestor results presentation
2nd Jul 20187:00 amRNSNotice of Results
28th Jun 20187:00 amRNSDisposal of infectious disease business
21st May 20187:00 amRNSVISITECT CD4 development update
8th May 20187:00 amRNSAllersys? CE-Mark
2nd May 20187:41 amRNSClosure of Omega Diagnostics GmbH
24th Apr 20185:04 pmRNSPDMR Dealing
24th Apr 20187:00 amRNSHolding(s) in Company
23rd Apr 20183:50 pmRNSHolding(s) in Company
23rd Apr 20182:24 pmRNSDirector/PDMR Shareholding
23rd Apr 20182:22 pmRNSHolding(s) in Company
23rd Apr 20189:31 amRNSDirector/PDMR Shareholding
20th Apr 20187:00 amRNSAllersys Distribution Agreement
19th Apr 201811:45 amRNSInvestor Evening
10th Apr 20184:35 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.